{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:14:01Z","timestamp":1769631241309,"version":"3.49.0"},"reference-count":30,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Educ Pract Ed"],"accepted":{"date-parts":[[2013,5,13]]},"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In recent times, paediatric pulmonary arterial hypertension management has been transformed to focus on disease modifying strategies that improve both quality of life and survival, rather than just symptom palliation. Sildenafil, a phosphodiesterase-V inhibitor, has been at the centre of this. Despite controversial beginnings, its success in treating pulmonary arterial hypertension has led to its consideration for related pathologies such as persistent pulmonary hypertension of the newborn and bronchopulmonary dysplasia, as well as the development of a range of alternative formulations. However, this has caused its own controversy and confusion regarding the use of sildenafil in younger patients. In addition, recent data regarding long-term mortality and the repeal of US drugs approval have complicated the issue. Despite such setbacks, sildenafil continues to be a major component of the contemporary care of paediatric pulmonary hypertension in a variety of contexts, and this does not seem likely to change in the foreseeable future.<\/jats:p>","DOI":"10.1136\/archdischild-2013-303981","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T20:09:00Z","timestamp":1371326940000},"page":"141-147","source":"Crossref","is-referenced-by-count":27,"title":["Paediatric pulmonary hypertension and sildenafil: current practice and controversies"],"prefix":"10.1136","volume":"98","author":[{"given":"A J","family":"Wardle","sequence":"first","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M R","family":"Tulloh","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"},{"name":"Department of Paediatric Cardiology, University Hospitals Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,6,15]]},"reference":[{"key":"2025090221491495000_98.4.141.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139009"},{"key":"2025090221491495000_98.4.141.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.012"},{"key":"2025090221491495000_98.4.141.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.026591"},{"key":"2025090221491495000_98.4.141.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0598-8"},{"key":"2025090221491495000_98.4.141.5","unstructured":"Rich S . Primary pulmonary hypertension: executive summary. Evian, France: World Health Organization, 1998."},{"key":"2025090221491495000_98.4.141.6","doi-asserted-by":"publisher","DOI":"10.2165\/0148581-200911010-00001"},{"key":"2025090221491495000_98.4.141.7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1017\/S1047951103000891","article-title":"Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease","volume":"13","author":"Tulloh","year":"2003","journal-title":"Cardiol Young"},{"key":"2025090221491495000_98.4.141.8","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.072314"},{"key":"2025090221491495000_98.4.141.9","first-page":"3S","article-title":"Oral sildenafil treatment in children with pulmonary arterial hypertension: results of a double-blind, placebo-controlled, dose-ranging study","volume":"34","author":"Barst","year":"2009","journal-title":"Eur Respir J"},{"key":"2025090221491495000_98.4.141.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.016667"},{"key":"2025090221491495000_98.4.141.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03831.x"},{"key":"2025090221491495000_98.4.141.12","doi-asserted-by":"publisher","DOI":"10.1177\/0885066608321389"},{"key":"2025090221491495000_98.4.141.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200605-694OC"},{"key":"2025090221491495000_98.4.141.14","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e318213aac2"},{"key":"2025090221491495000_98.4.141.15","doi-asserted-by":"crossref","unstructured":"Shah PS Ohlsson A . Sildena\ufb01l for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011;8:CD005494.","DOI":"10.1002\/14651858.CD005494.pub3"},{"key":"2025090221491495000_98.4.141.16","unstructured":"Clinicaltrials.gov. US National Institutes Health. Sildenafil in persistent pulmonary hypertension in newborns. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01558466?term=sildenafil+pphn&rank (accessed 22 Jan 2013)."},{"key":"2025090221491495000_98.4.141.17","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e328332e745"},{"key":"2025090221491495000_98.4.141.18","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2011.131"},{"key":"2025090221491495000_98.4.141.19","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21415"},{"key":"2025090221491495000_98.4.141.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-008-9260-x"},{"key":"2025090221491495000_98.4.141.21","doi-asserted-by":"crossref","unstructured":"Wardle AJ, Wardle R, Luyt K, et al. The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Arch Dis Child Published Online First: 26 April 2013. doi:10.1136\/archdischild-2012-303333.","DOI":"10.1136\/archdischild-2012-303333"},{"key":"2025090221491495000_98.4.141.22","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.153684"},{"key":"2025090221491495000_98.4.141.23","unstructured":"Clinicaltrials.gov. US National Institutes Health. Sildenafil for severe diaphragmatic hernia. http:\/\/clinicaltrials.gov\/show\/NCT00133679 (accessed 19 Apr 2013)."},{"key":"2025090221491495000_98.4.141.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.655266"},{"key":"2025090221491495000_98.4.141.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2004.09.002"},{"key":"2025090221491495000_98.4.141.26","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.9.827"},{"key":"2025090221491495000_98.4.141.27","unstructured":"Pfizer Labs. Revatio patient information leaflet. New York: Pfizer Limited 2012, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS."},{"key":"2025090221491495000_98.4.141.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e554"},{"key":"2025090221491495000_98.4.141.29","unstructured":"National Specialised Commissioning Group NHS. Commissioning Policy Targeted therapies for the treatment of pulmonary hypertension in adults. London: NHS, 2012."},{"key":"2025090221491495000_98.4.141.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13490","article-title":"Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic","volume":"13","author":"Chen","year":"2009","journal-title":"Health Technol Assess"}],"container-title":["Archives of disease in childhood - Education &amp; practice edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2013-303981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:49:26Z","timestamp":1756874966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ep.bmj.com\/lookup\/doi\/10.1136\/archdischild-2013-303981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,15]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,7,11]]},"published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1136\/archdischild-2013-303981"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2013-303981","relation":{},"ISSN":["1743-0585","1743-0593"],"issn-type":[{"value":"1743-0585","type":"print"},{"value":"1743-0593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,15]]}}}